We are live on ! Find out more
RP

Regeneron Pharmaceuticals Portfolio holdings

AUM $177M
1-Year Est. Return 9.82%
This Fund
S&P 500
This Quarter Est. Return
+42.07%
1 Year Est. Return
+9.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$47.9M
AUM Growth
+$14.1M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
–
Closed
–

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
1
Intellia Therapeutics
NTLA
$1.67B
$47.5M 99.14%
3,702,995
– –
ACET icon
2
Adicet Bio
ACET
$74.7M
$412K 0.86%
60,511
– –

Similar funds

ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
AGC
Alden Global Capital Brandon, Florida $177M AUM 32.31% 1-Year Est. Return
CTC
Cetera Trust Company St. Paul, Minnesota $177M AUM 28.75% 1-Year Est. Return
ACM
Ararat Capital Management Westport, Connecticut $178M AUM 26.61% 1-Year Est. Return
NRWA
North Ridge Wealth Advisors Beaverton, Oregon $178M AUM 12.81% 1-Year Est. Return
SMTF
Sphera Management Technology Funds Tel Aviv, Israel $178M AUM 42.1% 1-Year Est. Return
XWL
XXI Wealth LLC Chicago, Illinois $177M AUM
MFFIA
McIntyre, Freedman & Flynn Investment Advisers Orleans, Massachusetts $176M AUM 42.57% 1-Year Est. Return

Regeneron Pharmaceuticals's Q1 2026 Portfolio in Review

As of Q1 2026, Regeneron Pharmaceuticals held 2 positions worth $47.9M, up 42% from $33.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2026: portfolio turnover was 0%. Regeneron Pharmaceuticals opened no new positions and made no exits, leaving the 2-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Regeneron Pharmaceuticals's ten largest holdings make up 100% of its $47.9M portfolio in Q1 2026.
  • Regeneron Pharmaceuticals opened 0 new positions and closed 0 in Q1 2026.
  • Regeneron Pharmaceuticals's portfolio value rose 42% quarter-over-quarter to $47.9M.

Based on Regeneron Pharmaceuticals's 13F filing for Q1 2026, filed 8 May 2026.